share_log

Canaccord Genuity Maintains Buy on Inari Medical, Raises Price Target to $94

Benzinga Real-time News ·  Sep 16, 2022 07:56

Canaccord Genuity analyst William Plovanic maintains Inari Medical (NASDAQ:NARI) with a Buy and raises the price target from $92 to $94.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment